首页 > 最新文献

Clinical Epigenetics最新文献

英文 中文
DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma. DNMT1和DNMT3A驱动的DNA高甲基化有利于肿瘤免疫逃逸,有助于肾上腺皮质癌的侵袭性。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-08-02 DOI: 10.1186/s13148-023-01534-5
Gwenneg Kerdivel, Floriane Amrouche, Marie-Ange Calmejane, Floriane Carallis, Juliette Hamroune, Constanze Hantel, Jérôme Bertherat, Guillaume Assié, Valentina Boeva

Background: Adrenocortical carcinoma is rare and aggressive endocrine cancer of the adrenal gland. Within adrenocortical carcinoma, a recently described subtype characterized by a CpG island methylator phenotype (CIMP) has been associated with an especially poor prognosis. However, the drivers of CIMP remain unknown. Furthermore, the functional relation between CIMP and poor clinical outcomes of patients with adrenocortical carcinoma stays elusive.

Results: Here, we show that CIMP in adrenocortical carcinoma is linked to the increased expression of DNA methyltransferases DNMT1 and DNMT3A driven by a gain of gene copy number and cell hyperproliferation. Importantly, we demonstrate that CIMP contributes to tumor aggressiveness by favoring tumor immune escape. This effect could be at least partially reversed by treatment with the demethylating agent 5-azacytidine.

Conclusions: In sum, our findings suggest that co-treatment with demethylating agents might enhance the efficacy of immunotherapy and could represent a novel therapeutic approach for patients with high CIMP adrenocortical carcinoma.

背景:肾上腺皮质癌是一种罕见的侵袭性肾上腺内分泌癌。在肾上腺皮质癌中,最近描述的一种以CpG岛甲基化表型(CIMP)为特征的亚型与特别差的预后相关。然而,CIMP的驱动因素仍然未知。此外,CIMP与肾上腺皮质癌患者临床预后不良之间的功能关系尚不明确。结果:在这里,我们发现CIMP在肾上腺皮质癌中与DNA甲基转移酶DNMT1和DNMT3A的表达增加有关,这是由基因拷贝数的增加和细胞过度增殖驱动的。重要的是,我们证明了CIMP通过促进肿瘤免疫逃逸来促进肿瘤的侵袭性。用去甲基化剂5-氮杂胞苷治疗至少可以部分逆转这种效应。结论:总之,我们的研究结果表明,与去甲基化药物联合治疗可能会提高免疫治疗的疗效,并可能为高CIMP肾上腺皮质癌患者提供一种新的治疗方法。
{"title":"DNA hypermethylation driven by DNMT1 and DNMT3A favors tumor immune escape contributing to the aggressiveness of adrenocortical carcinoma.","authors":"Gwenneg Kerdivel,&nbsp;Floriane Amrouche,&nbsp;Marie-Ange Calmejane,&nbsp;Floriane Carallis,&nbsp;Juliette Hamroune,&nbsp;Constanze Hantel,&nbsp;Jérôme Bertherat,&nbsp;Guillaume Assié,&nbsp;Valentina Boeva","doi":"10.1186/s13148-023-01534-5","DOIUrl":"https://doi.org/10.1186/s13148-023-01534-5","url":null,"abstract":"<p><strong>Background: </strong>Adrenocortical carcinoma is rare and aggressive endocrine cancer of the adrenal gland. Within adrenocortical carcinoma, a recently described subtype characterized by a CpG island methylator phenotype (CIMP) has been associated with an especially poor prognosis. However, the drivers of CIMP remain unknown. Furthermore, the functional relation between CIMP and poor clinical outcomes of patients with adrenocortical carcinoma stays elusive.</p><p><strong>Results: </strong>Here, we show that CIMP in adrenocortical carcinoma is linked to the increased expression of DNA methyltransferases DNMT1 and DNMT3A driven by a gain of gene copy number and cell hyperproliferation. Importantly, we demonstrate that CIMP contributes to tumor aggressiveness by favoring tumor immune escape. This effect could be at least partially reversed by treatment with the demethylating agent 5-azacytidine.</p><p><strong>Conclusions: </strong>In sum, our findings suggest that co-treatment with demethylating agents might enhance the efficacy of immunotherapy and could represent a novel therapeutic approach for patients with high CIMP adrenocortical carcinoma.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9943494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer. PAX1低甲基化作为宫颈癌放射耐药的预后生物标志物。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-08-02 DOI: 10.1186/s13148-023-01538-1
Xuanxuan Li, Huan Liu, Xue Zhou, Yangying Zhou, Yu Zhang, Yu-Ligh Liou, Manting Zeng, Hong Zhu

Background: PAX1 gene methylation plays an important role in the development of cervical cancer. However, its prognostic value after radiotherapy for locally advanced cervical cancer is unknown, so this study aimed to investigate the value of PAX1 gene methylation for predicting the sensitivity of radiotherapy for cervical cancer.

Methods: We selected 125 patients with primary cervical cancer who underwent concurrent chemo-radiotherapy as the study population, quantitative methylation-specific polymerase chain reaction (QMSP) was used for detecting PAX1 methylation status of cervical exfoliated cells. Logistic regression model was used to analyze the risk factors associated with the short-term efficacy and to establish a prediction model of radiotherapy sensitivity based on PAX1 gene methylation. Cell viability after radiation of Hela and SiHa cells transfected with PAX1 or control vector was evaluated by CCK8. Furthermore, RNA-Seq analyses identified different expressed genes (DEGs) in PAX1 overexpressed SiHa cells. Gene Ontology (GO) and pathway enrichment analysis was carried out to determine the biological function of DEGs.

Results: PAX1 methylation level was associated with HPV16/18-positive rate. PAX1 hypomethylation was found to be a risk factor for tumor residual after chemo-radiotherapy. A nomogram containing the risk factors for PAX1 methylation status, lymph node metastasis, pathological type and tumor size was further constructed to predict the probability of tumor residual after chemo-radiotherapy (AUC = 0.823, 95% CI 0.736-0.910). High PAX1 protein level was more likely to cause radioresistance in both Hela and SiHa cells. Transcriptomic sequencing of PAX1 overexpressed and control cells identified 615 differentially expressed genes, and GO enrichment analysis suggested that PAX1 may be involved in the regulation of signaling receptor activity and response to viruses.

Conclusion: PAX1 hypomethylation status could be used as a promising biomarker to predict radioresistance in cervical cancer. This further provides a new idea for the individualized treatment strategy of simultaneous radiotherapy for cervical cancer.

背景:PAX1基因甲基化在宫颈癌的发生发展中起重要作用。但其在局部晚期宫颈癌放疗后的预后价值尚不清楚,因此本研究旨在探讨PAX1基因甲基化对宫颈癌放疗敏感性的预测价值。方法:选择125例同步放化疗的原发性宫颈癌患者作为研究人群,采用定量甲基化特异性聚合酶链反应(QMSP)检测宫颈脱落细胞PAX1甲基化状态。采用Logistic回归模型分析影响短期疗效的危险因素,建立基于PAX1基因甲基化的放疗敏感性预测模型。用CCK8评价转染PAX1或对照载体的Hela和SiHa细胞辐照后的细胞活力。此外,RNA-Seq分析在PAX1过表达的SiHa细胞中鉴定了不同的表达基因(DEGs)。通过基因本体(Gene Ontology, GO)和途径富集分析来确定DEGs的生物学功能。结果:PAX1甲基化水平与hpv16 /18阳性率相关。PAX1低甲基化被发现是化疗后肿瘤残留的危险因素。进一步构建包含PAX1甲基化状态、淋巴结转移、病理类型和肿瘤大小等危险因素的nomogram预测放化疗后肿瘤残留概率(AUC = 0.823, 95% CI 0.736-0.910)。高PAX1蛋白水平更容易引起Hela和SiHa细胞的辐射抗性。PAX1过表达细胞和对照细胞转录组测序鉴定出615个差异表达基因,GO富集分析提示PAX1可能参与信号受体活性调控和病毒应答。结论:PAX1低甲基化状态可作为预测宫颈癌放射耐药的生物标志物。这进一步为宫颈癌同步放疗的个体化治疗策略提供了新的思路。
{"title":"PAX1 hypomethylation as a prognostic biomarker for radioresistance of cervical cancer.","authors":"Xuanxuan Li,&nbsp;Huan Liu,&nbsp;Xue Zhou,&nbsp;Yangying Zhou,&nbsp;Yu Zhang,&nbsp;Yu-Ligh Liou,&nbsp;Manting Zeng,&nbsp;Hong Zhu","doi":"10.1186/s13148-023-01538-1","DOIUrl":"https://doi.org/10.1186/s13148-023-01538-1","url":null,"abstract":"<p><strong>Background: </strong>PAX1 gene methylation plays an important role in the development of cervical cancer. However, its prognostic value after radiotherapy for locally advanced cervical cancer is unknown, so this study aimed to investigate the value of PAX1 gene methylation for predicting the sensitivity of radiotherapy for cervical cancer.</p><p><strong>Methods: </strong>We selected 125 patients with primary cervical cancer who underwent concurrent chemo-radiotherapy as the study population, quantitative methylation-specific polymerase chain reaction (QMSP) was used for detecting PAX1 methylation status of cervical exfoliated cells. Logistic regression model was used to analyze the risk factors associated with the short-term efficacy and to establish a prediction model of radiotherapy sensitivity based on PAX1 gene methylation. Cell viability after radiation of Hela and SiHa cells transfected with PAX1 or control vector was evaluated by CCK8. Furthermore, RNA-Seq analyses identified different expressed genes (DEGs) in PAX1 overexpressed SiHa cells. Gene Ontology (GO) and pathway enrichment analysis was carried out to determine the biological function of DEGs.</p><p><strong>Results: </strong>PAX1 methylation level was associated with HPV16/18-positive rate. PAX1 hypomethylation was found to be a risk factor for tumor residual after chemo-radiotherapy. A nomogram containing the risk factors for PAX1 methylation status, lymph node metastasis, pathological type and tumor size was further constructed to predict the probability of tumor residual after chemo-radiotherapy (AUC = 0.823, 95% CI 0.736-0.910). High PAX1 protein level was more likely to cause radioresistance in both Hela and SiHa cells. Transcriptomic sequencing of PAX1 overexpressed and control cells identified 615 differentially expressed genes, and GO enrichment analysis suggested that PAX1 may be involved in the regulation of signaling receptor activity and response to viruses.</p><p><strong>Conclusion: </strong>PAX1 hypomethylation status could be used as a promising biomarker to predict radioresistance in cervical cancer. This further provides a new idea for the individualized treatment strategy of simultaneous radiotherapy for cervical cancer.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10297235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypomethylation of ABCG1 in peripheral blood as a potential marker for the detection of coronary heart disease. 外周血中ABCG1低甲基化作为检测冠心病的潜在标志物
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-28 DOI: 10.1186/s13148-023-01533-6
Jialie Jin, Xiaojing Zhao, Chao Zhu, Mengxia Li, Jinxin Wang, Yao Fan, Chunlan Liu, Chong Shen, Rongxi Yang

Background: Novel molecular biomarkers for the risk assessment and early detection of coronary heart disease (CHD) are urgently needed for disease prevention. Altered methylation of ATP-binding cassette subfamily G member 1 (ABCG1) has been implicated in CHD but was mostly studied in Caucasians. Exploring the potential relationship between ABCG1 methylation in blood and CHD among the Chinese population would yield valuable insights.

Methods: Peripheral blood samples were obtained from a case-control study (287 CHD patients vs. 277 controls) and a prospective nested case-control study (171 CHD patients and 197 matched controls). DNA extraction and bisulfite-specific PCR amplification techniques were employed for sample processing. Quantitative assessment of methylation levels was conducted using mass spectrometry. Statistical analyses involved the utilization of logistic regression and nonparametric tests.

Results: We found hypomethylation of ABCG1 in whole blood was associated with the risk of CHD in both studies, which was enhanced in heart failure (HF) patients, female and younger subjects. When combined with baseline characteristics, altered ABCG1 methylation showed improved predictive effect for differentiating CHD cases, ischemic cardiomyopathy (ICM) cases, younger than 60 years CHD cases, and female CHD cases from healthy controls (area under the curve (AUC) = 0.68, 0.71, 0.74, and 0.73, respectively).

Conclusions: We demonstrated a robust link between ABCG1 hypomethylation in whole blood and CHD risk in the Chinese population and provided novel evidence indicating that aberrant ABCG1 methylation in peripheral blood can serve as an early detection biomarker for CHD patients.

背景:冠心病(CHD)的风险评估和早期检测迫切需要新的分子生物标志物。atp结合盒亚家族G成员1 (ABCG1)甲基化改变与冠心病有关,但主要在白种人中进行研究。探索中国人群血液中ABCG1甲基化与冠心病之间的潜在关系将产生有价值的见解。方法:外周血样本来自一项病例对照研究(287例冠心病患者对277例对照组)和一项前瞻性巢式病例对照研究(171例冠心病患者和197例匹配对照组)。采用DNA提取和亚硫酸盐特异性PCR扩增技术对样品进行处理。采用质谱法对甲基化水平进行定量评估。统计分析包括使用逻辑回归和非参数检验。结果:我们发现,在两项研究中,全血中ABCG1的低甲基化与冠心病的风险相关,这在心力衰竭(HF)患者、女性和年轻受试者中有所增强。结合基线特征,改变的ABCG1甲基化对区分冠心病病例、缺血性心肌病(ICM)病例、60岁以下冠心病病例和健康对照女性冠心病患者有更好的预测作用(曲线下面积(AUC)分别为0.68、0.71、0.74和0.73)。结论:我们证明了全血中ABCG1低甲基化与中国人群冠心病风险之间的强大联系,并提供了新的证据,表明外周血中异常的ABCG1甲基化可以作为冠心病患者的早期检测生物标志物。
{"title":"Hypomethylation of ABCG1 in peripheral blood as a potential marker for the detection of coronary heart disease.","authors":"Jialie Jin,&nbsp;Xiaojing Zhao,&nbsp;Chao Zhu,&nbsp;Mengxia Li,&nbsp;Jinxin Wang,&nbsp;Yao Fan,&nbsp;Chunlan Liu,&nbsp;Chong Shen,&nbsp;Rongxi Yang","doi":"10.1186/s13148-023-01533-6","DOIUrl":"https://doi.org/10.1186/s13148-023-01533-6","url":null,"abstract":"<p><strong>Background: </strong>Novel molecular biomarkers for the risk assessment and early detection of coronary heart disease (CHD) are urgently needed for disease prevention. Altered methylation of ATP-binding cassette subfamily G member 1 (ABCG1) has been implicated in CHD but was mostly studied in Caucasians. Exploring the potential relationship between ABCG1 methylation in blood and CHD among the Chinese population would yield valuable insights.</p><p><strong>Methods: </strong>Peripheral blood samples were obtained from a case-control study (287 CHD patients vs. 277 controls) and a prospective nested case-control study (171 CHD patients and 197 matched controls). DNA extraction and bisulfite-specific PCR amplification techniques were employed for sample processing. Quantitative assessment of methylation levels was conducted using mass spectrometry. Statistical analyses involved the utilization of logistic regression and nonparametric tests.</p><p><strong>Results: </strong>We found hypomethylation of ABCG1 in whole blood was associated with the risk of CHD in both studies, which was enhanced in heart failure (HF) patients, female and younger subjects. When combined with baseline characteristics, altered ABCG1 methylation showed improved predictive effect for differentiating CHD cases, ischemic cardiomyopathy (ICM) cases, younger than 60 years CHD cases, and female CHD cases from healthy controls (area under the curve (AUC) = 0.68, 0.71, 0.74, and 0.73, respectively).</p><p><strong>Conclusions: </strong>We demonstrated a robust link between ABCG1 hypomethylation in whole blood and CHD risk in the Chinese population and provided novel evidence indicating that aberrant ABCG1 methylation in peripheral blood can serve as an early detection biomarker for CHD patients.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9996172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genome-wide discovery of circulating cell-free DNA methylation biomarkers for colorectal cancer detection. 结肠直肠癌检测循环无细胞DNA甲基化生物标志物的全基因组发现。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-27 DOI: 10.1186/s13148-023-01518-5
Qingxiao Fang, Ziming Yuan, Hanqing Hu, Weiyuan Zhang, Guiyu Wang, Xishan Wang

Background: Colorectal polyp is known a precursor of colorectal cancer (CRC) that holds an increased risk for progression to CRC. Circulating cell-free DNA (cfDNA) methylation has shown favorable performance in the detection and monitoring the malignant progression in a variety of cancers.

Results: To discover cfDNA methylation markers for the diagnosis of CRC, we first performed a genome-wide analysis between eight CRC and eight polyp tissues using the Infinium HumanMethylationEPIC BeadChip. We identified 7008 DMCs, and after filtering, we validated 39 DMCs by MethylTarget sequencing in 62 CRC and 56 polyp tissues. A panel of four CpGs (cg04486886, cg06712559, cg13539460, and cg27541454) was selected as the methylation marker in tissue by LASSO and random forest models. A diagnosis prediction model was built based on the four CpGs, and the methylation diagnosis score (md-score) can effectively discriminate tissues with CRC from polyp patients (AUROC > 0.9). Finally, the cg27541454 was confirmed hypermethylated in CRC (AUC = 0.85) in the plasma validation cohort.

Conclusions: Our findings suggest that the md-score could robustly detect CRC from polyp tissues, and cg27541454 may be a promising candidate noninvasive biomarker for CRC early diagnosis.

背景:结直肠息肉是已知的结直肠癌(CRC)的前兆,其发展为CRC的风险增加。循环游离DNA (cfDNA)甲基化在多种癌症的恶性进展检测和监测中显示出良好的性能。结果:为了发现诊断CRC的cfDNA甲基化标记,我们首先使用Infinium HumanMethylationEPIC BeadChip对8个CRC和8个息肉组织进行了全基因组分析。我们鉴定了7008个DMCs,筛选后,我们通过MethylTarget测序在62个CRC和56个息肉组织中验证了39个DMCs。通过LASSO和随机森林模型选择4个CpGs (cg04486886、cg06712559、cg13539460和cg27541454)作为组织中的甲基化标记。基于4个CpGs构建诊断预测模型,甲基化诊断评分(md-score)可有效区分结直肠癌组织与息肉患者(AUROC > 0.9)。最后,在血浆验证队列中,cg27541454在CRC中被证实高甲基化(AUC = 0.85)。结论:我们的研究结果表明,md-score可以从息肉组织中检测出CRC, cg27541454可能是一种有希望的CRC早期诊断的非侵入性生物标志物。
{"title":"Genome-wide discovery of circulating cell-free DNA methylation biomarkers for colorectal cancer detection.","authors":"Qingxiao Fang,&nbsp;Ziming Yuan,&nbsp;Hanqing Hu,&nbsp;Weiyuan Zhang,&nbsp;Guiyu Wang,&nbsp;Xishan Wang","doi":"10.1186/s13148-023-01518-5","DOIUrl":"https://doi.org/10.1186/s13148-023-01518-5","url":null,"abstract":"<p><strong>Background: </strong>Colorectal polyp is known a precursor of colorectal cancer (CRC) that holds an increased risk for progression to CRC. Circulating cell-free DNA (cfDNA) methylation has shown favorable performance in the detection and monitoring the malignant progression in a variety of cancers.</p><p><strong>Results: </strong>To discover cfDNA methylation markers for the diagnosis of CRC, we first performed a genome-wide analysis between eight CRC and eight polyp tissues using the Infinium HumanMethylationEPIC BeadChip. We identified 7008 DMCs, and after filtering, we validated 39 DMCs by MethylTarget sequencing in 62 CRC and 56 polyp tissues. A panel of four CpGs (cg04486886, cg06712559, cg13539460, and cg27541454) was selected as the methylation marker in tissue by LASSO and random forest models. A diagnosis prediction model was built based on the four CpGs, and the methylation diagnosis score (md-score) can effectively discriminate tissues with CRC from polyp patients (AUROC > 0.9). Finally, the cg27541454 was confirmed hypermethylated in CRC (AUC = 0.85) in the plasma validation cohort.</p><p><strong>Conclusions: </strong>Our findings suggest that the md-score could robustly detect CRC from polyp tissues, and cg27541454 may be a promising candidate noninvasive biomarker for CRC early diagnosis.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9905795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer. 循环NPTX2甲基化作为转移性胰腺癌症预后和监测的非侵入性生物标志物。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-22 DOI: 10.1186/s13148-023-01535-4
María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano, Elizabeth Inga-Saavedra, Rosa María Rodríguez-Alonso, Silvia Guil-Luna, María Auxiliadora Gómez-España, Antonio Rodríguez-Ariza, Enrique Aranda

Background: Pancreatic cancer is the most lethal cancer with a dismal prognosis mainly due to diagnosis at advanced stage and ineffective treatments. CA19-9 levels and computed tomography (CT) imaging are the main standard criteria for evaluating disease progression and treatment response. In this study we explored liquid biopsy-based epigenetic biomarkers for prognosis and monitoring disease in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Methods: Plasma samples were collected from 44 mPDAC patients at the time of diagnosis, and in 15 of them, additional samples were obtained during follow-up of the disease. After cell-free DNA (cfDNA), isolation circulating levels of methylated NPTX2, SPARC, BMP3, SFRP1 and TFPI2 genes were measured using digital droplet PCR (ddPCR). BEAMing technique was performed for quantitation of RAS mutations in cfDNA, and CA19-9 was measured using standard techniques.

Results: NPTX2 was the most highly and frequently methylated gene in cfDNA samples from mPDAC patients. Higher circulating NPTX2 methylation levels at diagnosis were associated with poor prognosis and efficiently stratified patients for prediction of overall survival (6.06% cut-off, p = 0.0067). Dynamics of circulating NPTX2 methylation levels correlated with disease progression and response to therapy and predicted better than CA19-9 the evolution of disease in mPDAC patients. Remarkably, in many cases the disease progression detected by CT scan was anticipated by an increase in circulating NPTX2 methylation levels.

Conclusions: Our study supports circulating NPTX2 methylation levels as a promising liquid biopsy-based clinical tool for non-invasive prognosis, monitoring disease evolution and response to treatment in mPDAC patients.

背景:癌症是最致命的癌症,预后极差,主要是诊断晚期和治疗无效。CA19-9水平和计算机断层扫描(CT)成像是评估疾病进展和治疗反应的主要标准。在这项研究中,我们探索了基于液体活检的表观遗传学生物标志物,用于转移性胰腺导管腺癌(mPDAC)患者的预后和疾病监测。方法:在诊断时收集44名mPDAC患者的血浆样本,其中15人在疾病随访期间获得了额外的样本。在无细胞DNA(cfDNA)后,使用数字液滴PCR(ddPCR)测量甲基化NPTX2、SPARC、BMP3、SFRP1和TFPI2基因的分离循环水平。BEAMing技术用于定量cfDNA中的RAS突变,CA19-9使用标准技术进行测量。结果:在mPDAC患者的cfDNA样本中,NPTX2是甲基化程度最高、频率最高的基因。诊断时较高的循环NPTX2甲基化水平与预后不良相关,并有效地对患者进行分层预测总生存率(6.06%的临界值,p = 0.0067)。循环NPTX2甲基化水平的动力学与疾病进展和对治疗的反应相关,并且比CA19-9更好地预测mPDAC患者的疾病演变。值得注意的是,在许多情况下,CT扫描检测到的疾病进展是通过循环NPTX2甲基化水平的增加来预测的。结论:我们的研究支持循环NPTX2甲基化水平作为一种有前途的基于液体活检的临床工具,用于mPDAC患者的无创预后、监测疾病演变和治疗反应。
{"title":"Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer.","authors":"María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, María Teresa Cano, Elizabeth Inga-Saavedra, Rosa María Rodríguez-Alonso, Silvia Guil-Luna, María Auxiliadora Gómez-España, Antonio Rodríguez-Ariza, Enrique Aranda","doi":"10.1186/s13148-023-01535-4","DOIUrl":"10.1186/s13148-023-01535-4","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is the most lethal cancer with a dismal prognosis mainly due to diagnosis at advanced stage and ineffective treatments. CA19-9 levels and computed tomography (CT) imaging are the main standard criteria for evaluating disease progression and treatment response. In this study we explored liquid biopsy-based epigenetic biomarkers for prognosis and monitoring disease in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).</p><p><strong>Methods: </strong>Plasma samples were collected from 44 mPDAC patients at the time of diagnosis, and in 15 of them, additional samples were obtained during follow-up of the disease. After cell-free DNA (cfDNA), isolation circulating levels of methylated NPTX2, SPARC, BMP3, SFRP1 and TFPI2 genes were measured using digital droplet PCR (ddPCR). BEAMing technique was performed for quantitation of RAS mutations in cfDNA, and CA19-9 was measured using standard techniques.</p><p><strong>Results: </strong>NPTX2 was the most highly and frequently methylated gene in cfDNA samples from mPDAC patients. Higher circulating NPTX2 methylation levels at diagnosis were associated with poor prognosis and efficiently stratified patients for prediction of overall survival (6.06% cut-off, p = 0.0067). Dynamics of circulating NPTX2 methylation levels correlated with disease progression and response to therapy and predicted better than CA19-9 the evolution of disease in mPDAC patients. Remarkably, in many cases the disease progression detected by CT scan was anticipated by an increase in circulating NPTX2 methylation levels.</p><p><strong>Conclusions: </strong>Our study supports circulating NPTX2 methylation levels as a promising liquid biopsy-based clinical tool for non-invasive prognosis, monitoring disease evolution and response to treatment in mPDAC patients.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10362605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9858720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis. 更正:通过靶向DNA甲基化分析定量造血干细胞和祖细胞。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-20 DOI: 10.1186/s13148-023-01532-7
Ledio Bocova, Wouter Hubens, Cordula Engel, Steffen Koschmieder, Edgar Jost, Wolfgang Wagner
{"title":"Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis.","authors":"Ledio Bocova,&nbsp;Wouter Hubens,&nbsp;Cordula Engel,&nbsp;Steffen Koschmieder,&nbsp;Edgar Jost,&nbsp;Wolfgang Wagner","doi":"10.1186/s13148-023-01532-7","DOIUrl":"https://doi.org/10.1186/s13148-023-01532-7","url":null,"abstract":"","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9840250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abnormal DNA methylation within genes of the steroidogenesis pathway two years after paediatric critical illness and association with stunted growth in height further in time. 小儿危重疾病后两年类固醇生成途径基因内的异常DNA甲基化与身高发育迟缓的关系
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-19 DOI: 10.1186/s13148-023-01530-9
Ilse Vanhorebeek, Grégoire Coppens, Fabian Güiza, Inge Derese, Pieter J Wouters, Koen F Joosten, Sascha C Verbruggen, Greet Van den Berghe

Background: Former critically ill children show an epigenetic age deceleration 2 years after paediatric intensive care unit (PICU) admission as compared with normally developing healthy children, with stunted growth in height 2 years further in time as physical correlate. This was particularly pronounced in children who were 6 years or older at the time of critical illness. As this age roughly corresponds to the onset of adrenarche and further pubertal development, a relation with altered activation of endocrine pathways is plausible. We hypothesised that children who have been admitted to the PICU, sex- and age-dependently show long-term abnormal DNA methylation within genes involved in steroid hormone synthesis or steroid sulphation/desulphation, possibly aggravated by in-PICU glucocorticoid treatment, which may contribute to stunted growth in height further in time after critical illness.

Results: In this preplanned secondary analysis of the multicentre PEPaNIC-RCT and its follow-up, we compared the methylation status of genes involved in the biosynthesis of steroid hormones (aldosterone, cortisol and sex hormones) and steroid sulphation/desulphation in buccal mucosa DNA (Infinium HumanMethylation EPIC BeadChip) from former PICU patients at 2-year follow-up (n = 818) and healthy children with comparable sex and age (n = 392). Adjusting for technical variation and baseline risk factors and corrected for multiple testing (false discovery rate < 0.05), former PICU patients showed abnormal DNA methylation of 23 CpG sites (within CYP11A1, POR, CYB5A, HSD17B1, HSD17B2, HSD17B3, HSD17B6, HSD17B10, HSD17B12, CYP19A1, CYP21A2, and CYP11B2) and 4 DNA regions (within HSD17B2, HSD17B8, and HSD17B10) that were mostly hypomethylated. These abnormalities were partially sex- (1 CpG site) or age-dependent (7 CpG sites) and affected by glucocorticoid treatment (3 CpG sites). Finally, multivariable linear models identified robust associations of abnormal methylation of steroidogenic genes with shorter height further in time, at 4-year follow-up.

Conclusions: Children who have been critically ill show abnormal methylation within steroidogenic genes 2 years after PICU admission, which explained part of the stunted growth in height at 4-year follow-up. The abnormalities in DNA methylation may point to a long-term disturbance in the balance between active sex steroids and mineralocorticoids/glucocorticoids after paediatric critical illness, which requires further investigation.

背景:与正常发育的健康儿童相比,前危重儿童在进入儿科重症监护病房(PICU) 2年后表现出表观遗传年龄减速,与身体相关的身高发育迟缓时间进一步延长2年。这在6岁以上的儿童中尤其明显。由于这个年龄大致对应于肾上腺素的开始和进一步的青春期发育,因此与内分泌通路激活的改变有关是合理的。我们假设,已入住PICU的儿童,性别和年龄依赖于类固醇激素合成或类固醇磺化/脱硫相关基因的DNA甲基化长期异常,可能因PICU内糖皮质激素治疗而加剧,这可能导致危重疾病后进一步发育迟缓。结果:在这一预先计划的多中心PEPaNIC-RCT及其随访的二次分析中,我们比较了2年随访的PICU前患者(n = 818)和性别和年龄相似的健康儿童(n = 392)口腔粘膜DNA中参与类固醇激素(醛固酮、皮质醇和性激素)生物合成的基因的甲基化状态和类固醇硫酸/去硫(Infinium HumanMethylation EPIC BeadChip)。结论:危重儿童在PICU入院后2年出现类固醇基因甲基化异常,这部分解释了4年随访时身高发育迟缓的原因。DNA甲基化异常可能提示小儿危重疾病后活性性类固醇和矿糖皮质激素/糖皮质激素之间的平衡长期失调,有待进一步研究。
{"title":"Abnormal DNA methylation within genes of the steroidogenesis pathway two years after paediatric critical illness and association with stunted growth in height further in time.","authors":"Ilse Vanhorebeek,&nbsp;Grégoire Coppens,&nbsp;Fabian Güiza,&nbsp;Inge Derese,&nbsp;Pieter J Wouters,&nbsp;Koen F Joosten,&nbsp;Sascha C Verbruggen,&nbsp;Greet Van den Berghe","doi":"10.1186/s13148-023-01530-9","DOIUrl":"https://doi.org/10.1186/s13148-023-01530-9","url":null,"abstract":"<p><strong>Background: </strong>Former critically ill children show an epigenetic age deceleration 2 years after paediatric intensive care unit (PICU) admission as compared with normally developing healthy children, with stunted growth in height 2 years further in time as physical correlate. This was particularly pronounced in children who were 6 years or older at the time of critical illness. As this age roughly corresponds to the onset of adrenarche and further pubertal development, a relation with altered activation of endocrine pathways is plausible. We hypothesised that children who have been admitted to the PICU, sex- and age-dependently show long-term abnormal DNA methylation within genes involved in steroid hormone synthesis or steroid sulphation/desulphation, possibly aggravated by in-PICU glucocorticoid treatment, which may contribute to stunted growth in height further in time after critical illness.</p><p><strong>Results: </strong>In this preplanned secondary analysis of the multicentre PEPaNIC-RCT and its follow-up, we compared the methylation status of genes involved in the biosynthesis of steroid hormones (aldosterone, cortisol and sex hormones) and steroid sulphation/desulphation in buccal mucosa DNA (Infinium HumanMethylation EPIC BeadChip) from former PICU patients at 2-year follow-up (n = 818) and healthy children with comparable sex and age (n = 392). Adjusting for technical variation and baseline risk factors and corrected for multiple testing (false discovery rate < 0.05), former PICU patients showed abnormal DNA methylation of 23 CpG sites (within CYP11A1, POR, CYB5A, HSD17B1, HSD17B2, HSD17B3, HSD17B6, HSD17B10, HSD17B12, CYP19A1, CYP21A2, and CYP11B2) and 4 DNA regions (within HSD17B2, HSD17B8, and HSD17B10) that were mostly hypomethylated. These abnormalities were partially sex- (1 CpG site) or age-dependent (7 CpG sites) and affected by glucocorticoid treatment (3 CpG sites). Finally, multivariable linear models identified robust associations of abnormal methylation of steroidogenic genes with shorter height further in time, at 4-year follow-up.</p><p><strong>Conclusions: </strong>Children who have been critically ill show abnormal methylation within steroidogenic genes 2 years after PICU admission, which explained part of the stunted growth in height at 4-year follow-up. The abnormalities in DNA methylation may point to a long-term disturbance in the balance between active sex steroids and mineralocorticoids/glucocorticoids after paediatric critical illness, which requires further investigation.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9902964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of immune cell composition with the risk factors and incidence of acute coronary syndrome. 免疫细胞组成与危险因素和急性冠脉综合征发病率的关系
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-17 DOI: 10.1186/s13148-023-01527-4
Xian Shi, Minghan Qu, Yi Jiang, Ziwei Zhu, Chengguqiu Dai, Minghui Jiang, Lin Ding, Yu Yan, Chaolong Wang, Xiaomin Zhang, Shanshan Cheng, Xingjie Hao

Background: Although immune cells are involved in acute coronary syndrome (ACS), few studies have explored the association of incident ACS with the relative immune cell proportions. We aimed to investigate the association of immune cell proportions with the incidence and risk factors of ACS in the Dongfeng-Tongji cohort.

Methods: We conducted the analyses with 38,295 subjects from the first follow-up of the Dongfeng-Tongji cohort, including DNA methylation profiles for 1570 individuals. The proportions of immune cell types were observed from routine blood tests or estimated from DNA methylation profiles. For both observed and estimated immune cell proportions, we tested their associations with risk factors of ACS by multivariable linear regression models. In addition, the association of each immune cell proportion with incident ACS was assessed by the Cox regression model and conditional logistic regression model, respectively, adjusting for the risk factors of ACS.

Findings: The proportions of lymphocytes, monocytes, and neutrophils showed strong associations with sex, followed by diabetes. Moreover, sex and current smoking were the two factors with strongest association with the proportions of lymphocyte subtypes. The hazard ratio (HR) and 95% confidence interval (CI) of incident ACS per standard deviation (SD) increase in proportions of lymphocytes and neutrophils were 0.91 (0.85-0.96) and 1.10 (1.03-1.16), respectively. Furthermore, the OR (95% CI) of incident ACS per SD increase in proportions of NK cells, CD4+ T cells, and B cells were 0.88 (0.78-0.99), 1.15 (1.03-1.30), and 1.13 (1.00-1.26), respectively.

Interpretation: The proportions of immune cells were associated with several risk factors of ACS, including sex, diabetes, and current smoking. In addition, proportion of neutrophils had a risk effect, while proportion of lymphocytes had a protective effect on the incidence of ACS. The protective effect of lymphocytes was probably driven by NK cells.

背景:虽然免疫细胞参与急性冠脉综合征(ACS)的发生,但很少有研究探讨ACS的发生与相对免疫细胞比例的关系。我们的目的是探讨免疫细胞比例与东风-同济队列ACS发病率及危险因素的关系。方法:我们对东风-同济首次随访的38295名受试者进行了分析,包括1570名个体的DNA甲基化图谱。免疫细胞类型的比例从常规血液检查中观察或从DNA甲基化谱中估计。对于观察到的和估计的免疫细胞比例,我们通过多变量线性回归模型测试了它们与ACS危险因素的关联。此外,分别采用Cox回归模型和条件logistic回归模型评估各免疫细胞比例与ACS发生的相关性,并对ACS的危险因素进行调整。结果:淋巴细胞、单核细胞和中性粒细胞的比例与性别密切相关,其次是糖尿病。此外,性别和吸烟是与淋巴细胞亚型比例相关性最强的两个因素。淋巴细胞和中性粒细胞比例每标准差(SD)增加的发生率ACS的风险比(HR)和95%可信区间(CI)分别为0.91(0.85 ~ 0.96)和1.10(1.03 ~ 1.16)。此外,NK细胞、CD4+ T细胞和B细胞的发生率每SD增加的OR (95% CI)分别为0.88(0.78-0.99)、1.15(1.03-1.30)和1.13(1.00-1.26)。解释:免疫细胞的比例与ACS的几个危险因素有关,包括性别、糖尿病和当前吸烟。此外,中性粒细胞比例对ACS的发生有危险作用,而淋巴细胞比例对ACS的发生有保护作用。淋巴细胞的保护作用可能是由NK细胞驱动的。
{"title":"Association of immune cell composition with the risk factors and incidence of acute coronary syndrome.","authors":"Xian Shi,&nbsp;Minghan Qu,&nbsp;Yi Jiang,&nbsp;Ziwei Zhu,&nbsp;Chengguqiu Dai,&nbsp;Minghui Jiang,&nbsp;Lin Ding,&nbsp;Yu Yan,&nbsp;Chaolong Wang,&nbsp;Xiaomin Zhang,&nbsp;Shanshan Cheng,&nbsp;Xingjie Hao","doi":"10.1186/s13148-023-01527-4","DOIUrl":"https://doi.org/10.1186/s13148-023-01527-4","url":null,"abstract":"<p><strong>Background: </strong>Although immune cells are involved in acute coronary syndrome (ACS), few studies have explored the association of incident ACS with the relative immune cell proportions. We aimed to investigate the association of immune cell proportions with the incidence and risk factors of ACS in the Dongfeng-Tongji cohort.</p><p><strong>Methods: </strong>We conducted the analyses with 38,295 subjects from the first follow-up of the Dongfeng-Tongji cohort, including DNA methylation profiles for 1570 individuals. The proportions of immune cell types were observed from routine blood tests or estimated from DNA methylation profiles. For both observed and estimated immune cell proportions, we tested their associations with risk factors of ACS by multivariable linear regression models. In addition, the association of each immune cell proportion with incident ACS was assessed by the Cox regression model and conditional logistic regression model, respectively, adjusting for the risk factors of ACS.</p><p><strong>Findings: </strong>The proportions of lymphocytes, monocytes, and neutrophils showed strong associations with sex, followed by diabetes. Moreover, sex and current smoking were the two factors with strongest association with the proportions of lymphocyte subtypes. The hazard ratio (HR) and 95% confidence interval (CI) of incident ACS per standard deviation (SD) increase in proportions of lymphocytes and neutrophils were 0.91 (0.85-0.96) and 1.10 (1.03-1.16), respectively. Furthermore, the OR (95% CI) of incident ACS per SD increase in proportions of NK cells, CD4<sup>+</sup> T cells, and B cells were 0.88 (0.78-0.99), 1.15 (1.03-1.30), and 1.13 (1.00-1.26), respectively.</p><p><strong>Interpretation: </strong>The proportions of immune cells were associated with several risk factors of ACS, including sex, diabetes, and current smoking. In addition, proportion of neutrophils had a risk effect, while proportion of lymphocytes had a protective effect on the incidence of ACS. The protective effect of lymphocytes was probably driven by NK cells.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9899238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability selection enhances feature selection and enables accurate prediction of gestational age using only five DNA methylation sites. 稳定性选择增强了特征选择,只需使用五个 DNA 甲基化位点就能准确预测胎龄。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-13 DOI: 10.1186/s13148-023-01528-3
Kristine L Haftorn, Julia Romanowska, Yunsung Lee, Christian M Page, Per M Magnus, Siri E Håberg, Jon Bohlin, Astanand Jugessur, William R P Denault

Background: DNA methylation (DNAm) is robustly associated with chronological age in children and adults, and gestational age (GA) in newborns. This property has enabled the development of several epigenetic clocks that can accurately predict chronological age and GA. However, the lack of overlap in predictive CpGs across different epigenetic clocks remains elusive. Our main aim was therefore to identify and characterize CpGs that are stably predictive of GA.

Results: We applied a statistical approach called 'stability selection' to DNAm data from 2138 newborns in the Norwegian Mother, Father, and Child Cohort study. Stability selection combines subsampling with variable selection to restrict the number of false discoveries in the set of selected variables. Twenty-four CpGs were identified as being stably predictive of GA. Intriguingly, only up to 10% of the CpGs in previous GA clocks were found to be stably selected. Based on these results, we used generalized additive model regression to develop a new GA clock consisting of only five CpGs, which showed a similar predictive performance as previous GA clocks (R2 = 0.674, median absolute deviation = 4.4 days). These CpGs were in or near genes and regulatory regions involved in immune responses, metabolism, and developmental processes. Furthermore, accounting for nonlinear associations improved prediction performance in preterm newborns.

Conclusion: We present a methodological framework for feature selection that is broadly applicable to any trait that can be predicted from DNAm data. We demonstrate its utility by identifying CpGs that are highly predictive of GA and present a new and highly performant GA clock based on only five CpGs that is more amenable to a clinical setting.

背景:DNA 甲基化(DNAm)与儿童和成人的实际年龄以及新生儿的胎龄(GA)密切相关。由于这一特性,人们开发出了几种能准确预测儿童和成人生理年龄和胎龄的表观遗传时钟。然而,不同表观遗传时钟的预测性 CpGs 缺乏重叠,这一点仍然难以捉摸。因此,我们的主要目的是鉴定和描述能稳定预测 GA 的 CpGs:我们对挪威母亲、父亲和儿童队列研究(Norwegian Mother, Father, and Child Cohort study)中2138名新生儿的DNAm数据采用了一种名为 "稳定性选择"(stability selection)的统计方法。稳定性选择将子取样与变量选择相结合,以限制所选变量集中的错误发现数量。结果发现有 24 个 CpGs 可稳定地预测 GA。耐人寻味的是,在以前的 GA 时钟中,只有高达 10% 的 CpGs 被发现是稳定选择的。基于这些结果,我们使用广义加性模型回归法开发了一个仅由五个 CpGs 组成的新的 GA 时钟,其预测性能与以前的 GA 时钟相似(R2 = 0.674,中位绝对偏差 = 4.4 天)。这些 CpGs 位于或靠近涉及免疫反应、新陈代谢和发育过程的基因和调控区域。此外,非线性关联的考虑提高了早产新生儿的预测性能:我们提出了一种特征选择方法框架,它广泛适用于任何可通过 DNAm 数据预测的性状。我们通过识别对 GA 有高度预测作用的 CpGs 证明了这一方法的实用性,并提出了一种仅基于五个 CpGs 的新型高性能 GA 时钟,该时钟更适合临床环境。
{"title":"Stability selection enhances feature selection and enables accurate prediction of gestational age using only five DNA methylation sites.","authors":"Kristine L Haftorn, Julia Romanowska, Yunsung Lee, Christian M Page, Per M Magnus, Siri E Håberg, Jon Bohlin, Astanand Jugessur, William R P Denault","doi":"10.1186/s13148-023-01528-3","DOIUrl":"10.1186/s13148-023-01528-3","url":null,"abstract":"<p><strong>Background: </strong>DNA methylation (DNAm) is robustly associated with chronological age in children and adults, and gestational age (GA) in newborns. This property has enabled the development of several epigenetic clocks that can accurately predict chronological age and GA. However, the lack of overlap in predictive CpGs across different epigenetic clocks remains elusive. Our main aim was therefore to identify and characterize CpGs that are stably predictive of GA.</p><p><strong>Results: </strong>We applied a statistical approach called 'stability selection' to DNAm data from 2138 newborns in the Norwegian Mother, Father, and Child Cohort study. Stability selection combines subsampling with variable selection to restrict the number of false discoveries in the set of selected variables. Twenty-four CpGs were identified as being stably predictive of GA. Intriguingly, only up to 10% of the CpGs in previous GA clocks were found to be stably selected. Based on these results, we used generalized additive model regression to develop a new GA clock consisting of only five CpGs, which showed a similar predictive performance as previous GA clocks (R<sup>2</sup> = 0.674, median absolute deviation = 4.4 days). These CpGs were in or near genes and regulatory regions involved in immune responses, metabolism, and developmental processes. Furthermore, accounting for nonlinear associations improved prediction performance in preterm newborns.</p><p><strong>Conclusion: </strong>We present a methodological framework for feature selection that is broadly applicable to any trait that can be predicted from DNAm data. We demonstrate its utility by identifying CpGs that are highly predictive of GA and present a new and highly performant GA clock based on only five CpGs that is more amenable to a clinical setting.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis. FDA批准的IDH抑制剂治疗IDH突变急性髓性白血病的疗效和安全性:系统综述和荟萃分析。
IF 5.7 2区 医学 Q1 Medicine Pub Date : 2023-07-11 DOI: 10.1186/s13148-023-01529-2
Xiu Chen, Hongyun Xing, Xiaolu Xie, Liqiu Kou, Jun Li, Yaling Li

Objective: To systematically evaluate the efficacy and safety of FDA-approved isocitrate dehydrogenase (IDH) inhibitors in the treatment of IDH-mutated acute myeloid leukemia (AML).

Methods: We used R software to conduct a meta-analysis of prospective clinical trials of IDH inhibitors in the treatment of IDH-mutated AML published in PubMed, Embase, Clinical Trials, Cochrane Library and Web of Science from inception to November 15th, 2022.

Results: A total of 1109 IDH-mutated AML patients from 10 articles (11 cohorts) were included in our meta-analysis. The CR rate, ORR rate, 2-year survival (OS) rate and 2-year event-free survival (EFS) rate of newly diagnosed IDH-mutated AML (715 patients) were 47%, 65%, 45% and 29%, respectively. The CR rate, ORR rate, 2-year OS rate, median OS and median EFS of relapsed or refractory (R/R) IDH-mutated AML (394 patients) were 21%, 40%, 15%, 8.21 months and 4.73 months, respectively. Gastrointestinal adverse events were the most frequently occurring all-grade adverse events and hematologic adverse events were the most frequently occurring ≥ grade 3 adverse events.

Conclusion: IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be optimal therapeutic agents due to low CR rates. The safety of IDH inhibitors is controllable, but physicians should always pay attention to and manage the differentiation syndrome adverse events caused by IDH inhibitors. The above conclusions need more large samples and high-quality RCTs in the future to verify.

目的系统评估FDA批准的异柠檬酸脱氢酶(IDH)抑制剂治疗IDH突变急性髓性白血病(AML)的疗效和安全性:我们使用R软件对PubMed、Embase、Clinical Trials、Cochrane Library和Web of Science上发表的从开始到2022年11月15日IDH抑制剂治疗IDH突变AML的前瞻性临床试验进行了荟萃分析:荟萃分析共纳入了10篇文章(11个队列)中的1109例IDH突变AML患者。新诊断的IDH突变型AML患者(715例)的CR率、ORR率、2年生存率(OS)和2年无事件生存率(EFS)分别为47%、65%、45%和29%。复发或难治性(R/R)IDH突变型AML(394名患者)的CR率、ORR率、2年OS率、中位OS和中位EFS分别为21%、40%、15%、8.21个月和4.73个月。胃肠道不良事件是最常发生的所有级别不良事件,血液学不良事件是最常发生的≥3级不良事件:结论:IDH抑制剂是治疗IDH突变的R/R急性髓细胞白血病患者的一种很有前景的方法。对于新诊断的IDH突变急性髓细胞白血病患者,由于CR率较低,IDH抑制剂可能不是最佳治疗药物。IDH抑制剂的安全性是可控的,但医生应时刻关注和处理IDH抑制剂引起的分化综合征不良事件。上述结论需要未来更多的大样本和高质量的RCT来验证。
{"title":"Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.","authors":"Xiu Chen, Hongyun Xing, Xiaolu Xie, Liqiu Kou, Jun Li, Yaling Li","doi":"10.1186/s13148-023-01529-2","DOIUrl":"10.1186/s13148-023-01529-2","url":null,"abstract":"<p><strong>Objective: </strong>To systematically evaluate the efficacy and safety of FDA-approved isocitrate dehydrogenase (IDH) inhibitors in the treatment of IDH-mutated acute myeloid leukemia (AML).</p><p><strong>Methods: </strong>We used R software to conduct a meta-analysis of prospective clinical trials of IDH inhibitors in the treatment of IDH-mutated AML published in PubMed, Embase, Clinical Trials, Cochrane Library and Web of Science from inception to November 15th, 2022.</p><p><strong>Results: </strong>A total of 1109 IDH-mutated AML patients from 10 articles (11 cohorts) were included in our meta-analysis. The CR rate, ORR rate, 2-year survival (OS) rate and 2-year event-free survival (EFS) rate of newly diagnosed IDH-mutated AML (715 patients) were 47%, 65%, 45% and 29%, respectively. The CR rate, ORR rate, 2-year OS rate, median OS and median EFS of relapsed or refractory (R/R) IDH-mutated AML (394 patients) were 21%, 40%, 15%, 8.21 months and 4.73 months, respectively. Gastrointestinal adverse events were the most frequently occurring all-grade adverse events and hematologic adverse events were the most frequently occurring ≥ grade 3 adverse events.</p><p><strong>Conclusion: </strong>IDH inhibitor is a promising treatment for R/R AML patients with IDH mutations. For patients with newly diagnosed IDH-mutated AML, IDH inhibitors may not be optimal therapeutic agents due to low CR rates. The safety of IDH inhibitors is controllable, but physicians should always pay attention to and manage the differentiation syndrome adverse events caused by IDH inhibitors. The above conclusions need more large samples and high-quality RCTs in the future to verify.</p>","PeriodicalId":48652,"journal":{"name":"Clinical Epigenetics","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2023-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9899220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Epigenetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1